<DOC>
	<DOCNO>NCT00889681</DOCNO>
	<brief_summary>This Continued Access Protocol write allow ongoing treatment subject select investigational site market application Arctic Front® Cryoablation System review . This study also allow collection additional safety data follow modification implement Arctic Front® Catheter Cryoablation System .</brief_summary>
	<brief_title>Continued Access Protocol</brief_title>
	<detailed_description>1 . To evaluate safety treatment Arctic Front® Cardiac CryoAblation Catheter System , include Freezor® MAX Cardiac Cryoablation Catheter assess continuous survival subject free one primary safety outcome measures—Cryoablation Procedure Events ( CPEs ) Major Atrial Fibrillation Events ( MAFEs ) , adult patient paroxysmal atrial fibrillation fail one Atrial Fibrillation Drugs ( AFDs ) . 2 . To evaluate effectiveness treatment Arctic Front® Cardiac CryoAblation Catheter System , include Freezor® MAX Cardiac Cryoablation Catheter assess continuous survival subject success primary effectiveness outcome measure Long Term Clinical Success ( LTCS ) adult patient paroxysmal atrial fibrillation fail one Atrial Fibrillation Drugs ( AFDs ) . 3 . To evaluate acute performance modify Arctic Front® Cardiac CryoAblation Catheter System comparison Arctic Front® Cardiac CryoAblation Catheter System use PS-023 STOP AF Pivotal Trial .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Subjects must fulfill ALL follow criterion : 1 . Documented PAF : diagnosis paroxysmal atrial fibrillation ( PAF ) ( Section 9.1.18 , General Protocol Terminology ) , AND 2 episode AF 3 month precede Consent Date , least 1 must document trace 2 . 18 75 year age 3 . Failure treatment AF ( effectiveness intolerance ) one follow drug indicate treatment PAF : flecainide , propafenone , sotalol dofetilide . ANY follow regarded criterion exclude subject study : 1 . Any previous leave atrial ( LA ) ablation ( except permissible retreatment subject ) 2 . Any previous LA surgery 3 . Current intracardiac thrombus ( treat thrombus resolve ) 4 . Presence pulmonary vein stent 5 . Presence preexist pulmonary vein stenosis 6 . Preexisting hemidiaphragmatic paralysis 7 . Anteroposterior LA diameter &gt; 5.5 cm TTE 8 . Presence cardiac valve prosthesis 9 . Clinically significant mitral valve regurgitation stenosis 10 . Myocardial infarction , PCI / PTCA coronary artery stenting occur 3 month interval precede Consent Date 11 . Unstable angina 12 . Any cardiac surgery occur 3 month interval precede Consent Date 13 . Any significant congenital heart defect correct ( include atrial septal defect pulmonary vein abnormality include minor PFO ) 14 . NYHA class III IV congestive heart failure 15 . Left ventricular ejection fraction ( LVEF ) &lt; 40 % 16 . 2º ( Type II ) 3º atrioventricular block 17 . Presence permanent pacemaker , biventricular pacemaker , atrial defibrillator type implantable cardiac defibrillator ( without biventricular pace function ) 18 . Brugada syndrome 19 . Long QT syndrome 20 . Arrhythmogenic right ventricular dysplasia 21 . Sarcoidosis 22 . Hypertrophic cardiomyopathy 23 . Known cryoglobulinemia 24 . Uncontrolled hyperthyroidism 25 . Any cerebral ischemic event ( stroke TIAs ) occur 6 month interval precede Consent Date . 26 . Any woman know pregnant 27 . Any woman without freedom pregnancy demonstrate one follow condition : negative βHCG test within 7 day prior Start Date history surgical sterilization postmenopausal free menses least 12 month . 28 . Life expectancy le one ( 1 ) year 29 . Current anticipated participation clinical trial drug , device biologic duration study 30 . Unwilling unable comply fully study procedure followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>